InvestorsHub Logo
Post# of 251306
Next 10
Followers 828
Posts 119330
Boards Moderated 16
Alias Born 09/05/2002

Re: DewDiligence post# 217327

Friday, 02/23/2018 1:10:51 PM

Friday, February 23, 2018 1:10:51 PM

Post# of 251306
ENTA—Mavyret scripts plateaued in the week ending 2/16/18, showing 0.2% growth in NRx and 0.9% growth in TRx (according to IMS).

ABBV’s patient share for the week was 37.7% for NRx and 33.5% for TRx, both down slightly from the prior week (#msg-138602647).

Do these data mean that Mavyret's growth trajectory in the US market has materially changed? It's too soon to say, but I strongly doubt that.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.